[BidClub_]
143 episodes2 active
Language
Invest Like the BestEN · 72 min

Andrew Huberman - The Frontier of Neurotechnology - [Invest Like the Best, EP.494]

Patrick O'ShaughnessyAndrew Huberman

Sleep is the near-term neurotechnology wedge because users already accept physiological measurement, while an eye mask reportedly measures REM, induces sleep-promoting eye movements, and amplifies REM, with related technology expected in roughly seven to 12 months.Huberman predicts Meta, OpenAI, Anthropic, and Elon’s Neuralink effort will converge on neural read/write biotech, but missing models of memory and thought, plus a possible 2027-28 downturn in optimization content, remain key risks.

MoonshotsEN · 147 min

Recursive's $670M Bet on Self-Improving AI, Sonnet 5.5 Hits 70%, Elon Co-Leads Pentagon Push EP 299

Peter DiamandisSalim IsmailDave BlundinAlexander Wissner-GrossRichard Socher

Recursive’s $670 million raise, backed by Google Ventures, Greycroft, Nvidia, and AMD, targets weak recursive improvement as AI-generated code increasingly enters system design.Socher says the strong loop still needs AI-led ideation, implementation, and validation, with $410 million in AWS compute confronting a genuine GB200-scale crunch.Sonnet 5.5’s reportedly 70% Terminal Bench 4.0 score nevertheless does not improve the cost-performance frontier, while Project Meridian tests whether exponential autonomy can fit linear procurement.

Biotech HangoutEN · 60 min

Episode 198 - October 2, 2026

Graig SuvannavejhSam FazeliEric SchmidtBrian Skorney

Biotech’s 27% XBI gain through September masks a punishing ownership unwind, as underowned and heavily shorted names offset specialist-fund selling.Regeneron-Sanofi’s $1 billion upfront and AstraZeneca’s $2 billion Summit investment show strategic capital is flowing, but HARMONi-3 remains a potentially historic binary event.China-origin deals and Lilly’s obesity data sharpen competition, while financing, durability, tolerability, and endpoint risk still dictate outcomes.

The Cognitive RevolutionEN · 89 min

AI:AM: Was Trump-Xi Anything? What Counts as Utopia? + AWS GPUs Cost 3X & AI Diagnoses Rare Diseases

Nathan LabenzPrakash NarayananJeremie HarrisEdouard HarrisSteve HouJoel BorgenDaniel McKinnon

Trump-Xi contact could create an AI-crisis hotline, but without pre-vetted verification tools, an incident could trigger a demand to shut down a large cluster.Hyperscalers charge at least two to three times neo-cloud GPU prices; Gamo’s o3 loop found a 91-kilobase deletion, while Opus 5.5 scored about 50% on RareBench versus roughly 10% for LIRICAL.

MoonshotsEN · 44 min

Why We're Living in a Biological Singularity With Ben Lamm | MOONSHOTS Live #297

Peter DiamandisSalim IsmailDave BlundinAlexander Wissner-GrossBen Lamm

Colossal is now worth over $10 billion with more than four spin-offs, while AI connects fragmented research and addresses 40–60% replication failure through standardized language.That data infrastructure may matter more than the model itself as comparative genomics spans thousands of genomes.Colossal has surpassed 300 edits at over 90% efficiency and is testing 1,000, with large-fragment DNA synthesis and a fully extrauterine mammalian birth within 24 months as catalysts amid ethical and regulatory constraints.

All-InEN · 51 min

Daniel Ek: Life After Spotify, Broken Healthcare Incentives, Catching Disease Early & AI's Potential

Daniel Ek

Spotify passed 700 million active users and 300 million premium subscribers; Daniel Ek became executive chairman January 1 and returned to building.Neko's $499 unit-economic-positive visit combines 53 blood markers, 6,000 images and clinician review in roughly an hour.Over 100,000 scans found serious, previously undiagnosed conditions in roughly 1% of members; population outcomes and budget effects remain unresolved.

Biotech HangoutEN · 59 min

Episode 197 - September 25, 2026

Sam FazeliYaron WerberBrian SkorneyMatt Gline

Biotech’s healthy headline tape masked long-short degrossing and rate sensitivity, while 22 IPOs and record-period average proceeds showed primary-market resilience.MFN may rebalance global contributions through revenue sharing rather than simply cut U.S. prices, but Europe could restrict access or favor cheaper Chinese drugs; meanwhile, durable VK2735 efficacy, Celldex safety and Vertex’s interim analysis define catalysts.

Biotech HangoutEN · 55 min

Episode 196 - September 18, 2026

Josh SchimmerEric SchmidtPaul MatteisAdam Feuerstein

XBI fell roughly 4% month to date and 9%-10% from its highs, but remained up about 30% for the year, suggesting nervous consolidation rather than a broken thesis.Xenon’s nearly 30% selloff after pausing depression enrollment came despite no clinical hold and about 360 patients enrolled, showing how bounded safety data can become a franchise scare.Sionna’s failed add-on study reinforced Vertex’s cystic-fibrosis moat, while a switch study remains the key test.

硅谷101ZH · 55 min

E252|硅谷睡眠外挂:富人的玩具,还是预防医疗的入口?|对话Eight Sleep创始人

YiwenMatteo FranceschettiAlex Zatarain

Eight Sleep以实时响应而非单纯追踪形成差异化,AI可在睡眠期间调节温度、床头高度和声音。专利、自有传感器与专有数据构成护城河,中国是增长最快市场;FDA睡眠呼吸暂停检测与缓解审批是催化剂,但准确率仍未按任务明确。

Latent SpaceEN · 92 min

🔬Bio-security is an AI Arms Race - Eric Nguyen (CEO, Radical Numerics)

RJ HonickyEric Nguyen

Radical Numerics is positioning genome language models to move from reading DNA to designing functional sequences, with Omni’s post-training targeting variant effects in long-range, non-coding regions.The potential wedge is practical prediction across the roughly 98% of the human genome outside coding regions, while wet-lab validation, benchmark leakage, false positives, and biosecurity remain material execution risks.